AR 28
Alternative Names: AR28Latest Information Update: 28 Jun 2022
At a glance
- Originator Arbor Pharmaceuticals
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 28 Jun 2022 Discontinued - Phase-II for Skin disorders (unspecified route) (Azurity Pharmaceuticals pipeline, June 2022)
- 18 Mar 2021 No development reported - Phase-II for Skin disorders (unspecified route)
- 18 May 2018 Phase-II clinical trials in Skin disorders (unspecified route)